There are currently 79 active clinical trials seeking participants for Hepatocellular Carcinoma research studies. The states with the highest number of trials for Hepatocellular Carcinoma participants are California, Guangdong, Texas and New York.
T-Cell Therapy (ECT204) in Adults With Advanced HCC
NCT04864054
Recruiting
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents. Phase I has concluded and a Recommended Phase II Dose (RP2D) has been determined. We are now conducting Phase II to further confi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: City of Hope, Duarte, California +2 locations
Conditions: Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm, Metastatic Liver Cancer
Register for Updates
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients With Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
NCT05250895
Recruiting
This early phase I trial evaluates the use of hypoxia (lack of oxygen) as a measure in determining the outcome of Y90 selective internal radiation therapy in patients with liver cancer that has spread to a limited number of sites (oligometastatic). Radioembolization with Y90 is a minimally invasive procedure that combines embolization and radiation therapy to treat metastatic liver cancer. Tiny beads filled with radioactive isotope Y-90 are placed inside the blood vessel that provide blood suppl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatocellular Carcinoma
Register for Updates
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
NCT05641896
Recruiting
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic and colorectal cancer. The [18F]FAPI-74 PET scan will be acquired in patients with proven GI cancers after initial staging using institutional standard methods. The PET scan results will be compared to FAP immunohistochemistry (as the p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: University of California Los Angeles (UCLA) Health, Los Angeles, California +4 locations
Conditions: Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Hepatocellular Carcinoma
Register for Updates
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
NCT06034860
Recruiting
This is a Phase 1, open-label, dose escalation and expansion study of MT-8421 (an Engineered Toxin Body (ETB)) as monotherapy and in combination with nivolumab in patients with selected advanced solid cancer types. MT-8421 is an investigational drug that specifically targets and depletes cytotoxic T-lymphocytes-associated protein 4 (CTLA-4) expressing cells in an effort to directly dismantle the tumor microenvironment for the treatment of patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: The Angeles Clinic, Los Angeles, California +4 locations
Conditions: Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Arizona Health Research, Chandler, Arizona +58 locations
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842
Recruiting
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/18/2024
Locations: Research Site, Birmingham, Alabama +198 locations
Conditions: Hepatocellular Carcinoma
Register for Updates
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: UCLA - JCCC Clinical Research Unit, Los Angeles, California
Conditions: Advanced Solid Tumor, Hepatocellular Carcinoma
Register for Updates
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
NCT04550481
Recruiting
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver cancer. Liver fibrosis is the common finding of chronic liver diseases leading to reduced liver function. Lisinopril is a medication that is commonly used to treat high blood pressure. Lisinopril may help to decrease liver fibros... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/13/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California +3 locations
Conditions: Nonalcoholic Steatohepatitis, Hepatocellular Carcinoma
Register for Updates
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159
Recruiting
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Research Site, Birmingham, Alabama +58 locations
Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Register for Updates
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
NCT05176483
Recruiting
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in subjects with advanced solid tumors. In the Expansion Stage, the safety and efficacy of XL092 as monotherapy and in combination therapy will be further evaluated in t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Exelixis Clinical Site #67, Phoenix, Arizona +121 locations
Conditions: Renal Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer, Urothelial Carcinoma, Solid Tumor, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
NCT06342414
Recruiting
It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: City of Hope Medical Center, Duarte, California +4 locations
Conditions: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Primary Liver Cancer, Primary Liver Carcinoma, Hepatic Cancer, Hepatic Carcinoma
Register for Updates
Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres
NCT04903548
Recruiting
The overall objective of this research study is to evaluate outcomes associated with flex-dosing in Y90 SIR-Sphere administration in a prospective cohort of unresectable HCC patients eligible for segmental/super selective treatment at Methodist Dallas Medical Center (MDMC).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Hepatocellular Carcinoma
Register for Updates